Invention Grant
- Patent Title: Immunologic effector cell of targeted CLD18A2, and preparation method and use thereof
-
Application No.: US17522284Application Date: 2021-11-09
-
Publication No.: US12098199B2Publication Date: 2024-09-24
- Inventor: Huamao Wang , Bo Song , Xiumei Cai
- Applicant: CRAGE medical Co., Limited
- Applicant Address: CN Hong Kong
- Assignee: CRAGE MEDICAL CO., LIMITED
- Current Assignee: CRAGE MEDICAL CO., LIMITED
- Current Assignee Address: CN Hong Kong
- Agency: Wilson Sonsini Goodrich & Rosati
- Priority: CN 1410341504.X 2014.07.17
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K35/17 ; A61K48/00 ; C07K14/705 ; C07K14/725 ; C07K19/00 ; C12N5/10 ; C12N15/62 ; C12N15/867 ; A61K35/12
Abstract:
Disclosed are a chimeric antigen receptor (CAR) targeting CLD18A2, and preparation method and use thereof. The extracellular binding region of the CAR comprises a protein specifically recognizing CLD18A2. The immune effector cell modified by the CAR can be used to treat tumors such as pancreatic cancer and stomach cancer.
Public/Granted literature
- US20220363751A1 IMMUNOLOGIC EFFECTOR CELL OF TARGETED CLD18A2, AND PREPARATION METHOD AND USE THEREOF Public/Granted day:2022-11-17
Information query
